Antisense & RNAi Therapeutics Global Market Report 2025

Description

Antisense therapy involves the targeted and sequence-specific suppression of gene expression using single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and leads to the sequence-specific degradation of single-stranded target RNAs.

The primary technologies in antisense and RNAi therapeutics are RNA interference and antisense RNA. RNA interference is a conserved biological response to double-stranded RNA, which plays a role in resisting both endogenous parasitic and exogenous pathogenic nucleic acids, and it regulates the expression of protein-coding genes. Various routes of administration for these therapies include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other methods. These therapies are used for indications such as oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, and others.

The antisense & RNAi therapeutics market research report is one of a series of new reports from The Business Research Company that provides antisense & RNAi therapeutics market statistics, including antisense & RNAi therapeutics industry global market size, regional shares, competitors with antisense & RNAi therapeutics market share, detailed antisense & RNAi therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & RNAi therapeutics industry. This antisense & RNAi therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antisense & RNAi therapeutics market size has grown rapidly in recent years. It will grow from $1.75 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to a rise in funding, advancement in technologies, and rise in healthcare expenditure, rapid growth in the elderly population, and economic growth in emerging markets.

The antisense & RNAi therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.18 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to an increase in healthcare access, rising prevalence of cancer, and increasing demand for antisense and RNAi therapeutics due to COVID-19. Major trends in the forecast period include focus efforts towards the research and development of RNA therapeutics for orphan diseases, use of nanoparticles, development of new and improved antisense and RNAi therapeutics, and collaboration with other companies for product innovation and to drive revenues.

The increasing prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is expected to boost demand for the antisense and RNAi therapeutics market. Gene suppression techniques, such as RNA interference and antisense oligonucleotides, are utilized to treat various neurodegenerative conditions by repairing mutant genes. For example, a report from the American Heart Association, a U.S.-based organization, published in January 2024, indicated that the age-adjusted death rate from cardiovascular diseases rose to 233.3 per 100,000, marking a 4.0% increase from the previous year. Therefore, the growing incidence of neurodegenerative and infectious diseases is anticipated to drive the growth of the antisense and RNAi therapeutics market.

The increasing prevalence of chronic diseases is expected to drive demand for the antisense and RNAi therapeutics market. Chronic diseases are long-term health conditions that cannot be cured, encompassing illnesses such as cardiovascular diseases, oncological disorders, and others. Antisense and RNA interference (RNAi) therapeutics have demonstrated potential in treating various cardiovascular diseases by targeting specific genes or molecular pathways linked to the pathogenesis of these conditions. For example, the World Heart Report 2023, published by the World Health Organization (WHO), a U.S.-based specialized agency, revealed that in 2021, approximately 20.5 million individuals died from cardiovascular conditions, accounting for roughly one-third of all global deaths that year. Therefore, the rising prevalence of chronic diseases is anticipated to propel the growth of the antisense and RNAi therapeutics market.

Major companies in the antisense & RNAi therapeutics sector are employing strategic collaborations and partnerships as key initiatives to maintain their positions in an increasingly competitive market landscape. These partnerships involve joint efforts between two or more companies aiming to achieve shared objectives. For instance, in January 2023, Orbit Discovery Limited, a US-based company specializing in peptide discovery services, teamed up with SanegeneBio Inc., a UK-based firm focused on developing innovative RNAi-based medicines. This collaboration aims to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown. The partnership involves hit identification and cell-based internalization studies, leveraging Orbit's proprietary technology for rapid peptide lead discovery. Sanegene gains the opportunity to further develop potential hits derived from the screening activities for advanced RNAi therapeutics.

Major players in the antisense & RNAi therapeutics market are fostering partnerships to forge new relationships aimed at jointly creating innovative products. These strategic collaborations represent cooperative alliances between organizations, pooling their strengths or resources toward common goals. For example, in December 2022, GlaxoSmithKline (GSK), a UK-based pharmaceutical giant, and Wave Life Sciences, a US-based company specializing in genetic medicines, announced a collaboration to develop oligonucleotide therapeutics targeting novel genetic markers. By integrating GSK's genetic expertise with Wave's PRISM platform, the collaboration aims to advance up to eight preclinical programs. Additionally, GSK secures an exclusive global license for Wave's WVE-006, a potential RNA editing program targeting alpha-1 antitrypsin deficiency (AATD). Wave's PRISM platform uniquely offers three RNA-targeting modalities, leveraging innovative chemistry to optimize the properties of therapeutic oligonucleotides.

In July 2023, Alnylam, a U.S.-based biopharmaceutical company specializing in RNAi therapeutics, announced a strategic partnership with Roche, a Switzerland-based global healthcare company that develops medicines, diagnostics, and treatments. The partnership involves an initial investment of $310 million, with the total deal value potentially reaching up to $2.8 billion through various development, regulatory, and sales milestones. As part of this collaboration, the companies will co-develop and co-commercialize Zilebesiran, an investigational RNAi therapeutic aimed at treating hypertension in patients at high cardiovascular risk. This partnership combines Alnylam's expertise in RNAi therapeutics with Roche's extensive experience in drug development and commercialization, potentially transforming treatment options for patients with hypertension and high cardiovascular risk.

Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilac ve SaglIk Urunleri A.S., Egypt Otsuka Pharmaceutical

North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as at replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antisense & RNAi Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antisense & rnai therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antisense & rnai therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antisense & rnai therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA); Short Hairpin RNA (shRNA); Dicer-substrate siRNA; MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs); Morpholino Oligomers; Locked Nucleic Acids (LNAs); Gapmer Antisense Oligonucleotides
Companies Mentioned: Biogen Inc.; Ionis Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.; Arrowhead Pharmaceuticals Inc.; Moderna Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25458

1. Executive Summary

2. Antisense & RNAi Therapeutics Market Characteristics

3. Antisense & RNAi Therapeutics Market Trends And Strategies

4. Antisense & RNAi Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Antisense & RNAi Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Antisense & RNAi Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Antisense & RNAi Therapeutics Market Growth Rate Analysis
5.4. Global Antisense & RNAi Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Antisense & RNAi Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Antisense & RNAi Therapeutics Total Addressable Market (TAM)

6. Antisense & RNAi Therapeutics Market Segmentation

6.1. Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
RNA Interference
Antisense RNA
6.2. Global Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous Injections
Intra-dermal Injections
Other Delivery Methods
6.3. Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Cardiovascular Diseases (CVDs)
Respiratory Disorders
Neurological Disorders
Infectious Diseases
Other Indications
6.4. Global Antisense & RNAi Therapeutics Market, Sub-Segmentation Of RNA Interference (RNAi), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Interfering RNA (siRNA)
Short Hairpin RNA (shRNA)
Dicer-substrate siRNA
MicroRNA (miRNA) Based Therapeutics
6.5. Global Antisense & RNAi Therapeutics Market, Sub-Segmentation Of Antisense RNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antisense Oligonucleotides (ASOs)
Morpholino Oligomers
Locked Nucleic Acids (LNAs)
Gapmer Antisense Oligonucleotides

7. Antisense & RNAi Therapeutics Market Regional And Country Analysis

7.1. Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antisense & RNAi Therapeutics Market

8.1. Asia-Pacific Antisense & RNAi Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antisense & RNAi Therapeutics Market

9.1. China Antisense & RNAi Therapeutics Market Overview
9.2. China Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antisense & RNAi Therapeutics Market

10.1. India Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antisense & RNAi Therapeutics Market

11.1. Japan Antisense & RNAi Therapeutics Market Overview
11.2. Japan Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antisense & RNAi Therapeutics Market

12.1. Australia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antisense & RNAi Therapeutics Market

13.1. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antisense & RNAi Therapeutics Market

14.1. South Korea Antisense & RNAi Therapeutics Market Overview
14.2. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antisense & RNAi Therapeutics Market

15.1. Western Europe Antisense & RNAi Therapeutics Market Overview
15.2. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antisense & RNAi Therapeutics Market

16.1. UK Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antisense & RNAi Therapeutics Market

17.1. Germany Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antisense & RNAi Therapeutics Market

18.1. France Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antisense & RNAi Therapeutics Market

19.1. Italy Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antisense & RNAi Therapeutics Market

20.1. Spain Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antisense & RNAi Therapeutics Market

21.1. Eastern Europe Antisense & RNAi Therapeutics Market Overview
21.2. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antisense & RNAi Therapeutics Market

22.1. Russia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antisense & RNAi Therapeutics Market

23.1. North America Antisense & RNAi Therapeutics Market Overview
23.2. North America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antisense & RNAi Therapeutics Market

24.1. USA Antisense & RNAi Therapeutics Market Overview
24.2. USA Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antisense & RNAi Therapeutics Market

25.1. Canada Antisense & RNAi Therapeutics Market Overview
25.2. Canada Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antisense & RNAi Therapeutics Market

26.1. South America Antisense & RNAi Therapeutics Market Overview
26.2. South America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antisense & RNAi Therapeutics Market

27.1. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antisense & RNAi Therapeutics Market

28.1. Middle East Antisense & RNAi Therapeutics Market Overview
28.2. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antisense & RNAi Therapeutics Market

29.1. Africa Antisense & RNAi Therapeutics Market Overview
29.2. Africa Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles

30.1. Antisense & RNAi Therapeutics Market Competitive Landscape
30.2. Antisense & RNAi Therapeutics Market Company Profiles
- 30.2.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Antisense & RNAi Therapeutics Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. Dicerna Pharmaceuticals Inc.
31.3. Arbutus Biopharma Corporation
31.4. Acuitas Therapeutics
31.5. Adhera Therapeutics Inc.
31.6. EdiGene Inc.
31.7. Sirnaomics Inc.
31.8. Suzhou Ribo Life Science Co. Ltd
31.9. Biocon Limited
31.10. Quark Pharmaceuticals
31.11. GlaxoSmithKline Plc
31.12. Shanghai Junshi Biosciences Co. Ltd.
31.13. AstraZeneca
31.14. Benitec Biopharma Limited
31.15. Silence Therapeutics

32. Global Antisense & RNAi Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market

34. Recent Developments In The Antisense & RNAi Therapeutics Market

35. Antisense & RNAi Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Antisense & RNAi Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Antisense & RNAi Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Antisense & RNAi Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer